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Abstract The development of an antigen presentation system
based on the plum pox potyvirus (PPV) is here described. The
amino-terminal part of PPV capsid protein was chosen as the site
for expression of foreign antigenic peptides. Modifications in this
site were engineered to avoid the capability of natural transmis-
sion by aphids of this PPV vector. As a first practical attempt,
different forms of an antigenic peptide (single and tandem
repetition) from the VP2 capsid protein of canine parvovirus
(CPV) were expressed. Both chimeras are able to infect
Nicotiana clevelandii plants with similar characteristics to wild-
type virus and remain genetically stable after several plant
passages. The antigenicity of purified chimeric virions was
demonstrated, proving the suitability of this system for
diagnostic purposes. Moreover, mice and rabbits immunized
with chimeric virions developed CPV-specific antibodies, which
showed neutralizing activity.
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1. Introduction
Nowadays, plants are being engineered as novel biomanu-
facturing systems. Several advantages are o¡ered by plants in
comparison to other expression systems. In particular, they
are an inexpensive, safe and easy way to obtain proteins of
interest, not needing expensive manufacturing facilities for the
scaling-up, and allowing the replacement of traditional sur-
plus crops. The production of proteins of potential pharma-
ceutical value or subunit vaccines in plants is of particular
interest [1].
There are two major strategies for plant production of ther-
apeutic molecules: genetic transformation of the nuclear ge-
nome of plants to create transgenic plants, and manipulation
of the genome of plant viruses [1]. The latter strategy has the
advantage of causing plants to produce relatively large
amounts of the desired protein at a determined moment of
their developmental cycle; moreover, virus stocks can be
maintained without passages through plants for long periods
of time. In the particular case of peptide vaccines, the immu-
nogenicity of chemically synthesized peptides is enhanced by
conjugation to larger carrier molecules, especially when these
carrier molecules have a particulate structure [2]. The linkage
of epitopes on the surface of plant viral particles is, therefore,
a potential way to improve antigen presentation and to obtain
an e¡ective antibody response. Both ¢lamentous and icosahe-
dral plant viruses have been successfully developed as epitope
presentation systems [2^8] and in some cases as an alternative
to previous tissue culture-derived vaccines [9].
Plum pox virus (PPV) is a member of the plant potyvirus
group. The helicoidal virions are comprised of a messenger
polarity RNA molecule surrounded by more than 2000 copies
of a single capsid protein (CP) [10]. The potyvirus CP has
been implicated in several functions during the virus life cycle;
apart from the obvious function in encapsidation, this protein
holds an amino acid sequence (triad Asp-Ala-Gly) that is
essential for aphid transmission [11,12]. CP has also been in-
volved in potyvirus movement inside the plant for both cell-
to-cell and systemic movement. In particular, the amino- and
carboxy-terminal parts of CP have been implicated in long
distance movement [13^15]. Besides, both the amino- and car-
boxy-terminal parts of the CP have been previously described
to be surface exposed on the potyvirus virions and to be
highly immunogenic [16,17]. Naturally appearing PPV mu-
tants called NAT (non-aphid-transmissible) have been re-
ported [18,19]. These mutants have a 15 amino acid (aa) dele-
tion in the amino-terminal part of CP; this deletion includes
the glycine of the amino acid triad essential for transmission
by aphids.
The VP2 protein is the major structural protein of the ca-
nine parvovirus (CPV). There have been extensive studies and
¢ne mapping of epitopes of the VP2 protein amino-terminal
part, and synthetic vaccines against CPV based on peptides
have been described [20]. Among others, the 6L15 peptide has
previously shown the ability to induce neutralizing antibodies
against CPV in both mice and rabbits [21].
In this paper, the construction of an antigen presentation
system based on PPV is described. A full-length cDNA clone
of PPV [22] was used to engineer a mutant with a NAT-like
deletion and a unique cloning site MluI, which enables us to
introduce foreign sequences in that speci¢c region. This sys-
tem was used to produce chimeric PPV CPs containing im-
munologically active CPV-neutralizing epitopes.
2. Materials and methods
2.1. Construction of the chimeric clones
The BamHI-SacI fragment that contains the sequence encoding the
amino-terminal part of CP (extracted from the PPV full-length cDNA
clone pGPPV [22]) was introduced in M13mp19. Site-directed muta-
genesis was performed using the oligonucleotides 5P-GTGGTT-
GAAGTGCATCAACTTC-3P and 5P-GAGGTGGTTGTAACGCG-
TCAACTTCC-3P to create the NAT and NATMluI mutations, re-
spectively. The mutagenesis products were veri¢ed by sequencing, and
their BamHI-SacI fragments were cloned back in the full-length
cDNA clone creating pGPPV-NAT and pGPPV-NATMluI.
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An intermediate clone that contains the BamHI-SacI fragment of
pGPPV-NATMluI inserted in pUC18 (pUC18MluI) was constructed
to facilitate the cloning of sequences encoding antigenic peptides. The
sequence encoding the 6L15 CPV peptide was created by hybridizing
complementary oligonucleotides (plus strand: 5P-CGCGGTTCAAC-
CAGACGGTGGTCAACCTGCTGTCAGAAATGAACG-3P ; minus
strand: 5P-CGCGCGTTCATTTCTGACAGCAGGTTGACCACCG-
TCTGGTTGAAC-3P) which produced MluI-compatible overhangs.
The hybridization was carried out by incubating 1.5 Wg of each oli-
gonucleotide in a bu¡er containing 10 mM Tris-HCl pH 7.5, 100 mM
NaCl and 1 mM EDTA at 90‡C for 5 min, and then cooling down
slowly to room temperature. The hybridization mixture was ligated
with MluI-digested pUC18MluI, creating pUC18CPV. The BamHI-
SacI fragment of this plasmid, which contains the sequence encoding
the 6L15 peptide, was then introduced in the PPV full-length cDNA
clone, creating pGPPV-CPV.
To make the dimer-epitope clone pGPPV-2CPV, we followed the
same procedure described above, but the oligonucleotides were phos-
phorylated with T4-polynucleotide kinase before hybridization, and
pUC18MluI was treated with alkaline phosphatase after MluI diges-
tion. This allowed us to obtain pUC18-derived clones containing more
than a copy of the sequence coding for the CPV peptide. Clones with
two copies in the correct orientation were selected. The same proce-
dure as explained for one copy clone was performed to construct
pGPPV-2CPV from the intermediate clone.
2.2. In vitro transcription and plant inoculation
Capped transcripts from full-length cDNA clones were synthesized
with the T7 Cap Scribe transcription kit (Boehringer Mannheim), as
per the manufacturer’s instructions. 20 Wl of reaction mixture diluted
1:1 in 5 mM sodium phosphate bu¡er pH 7.5 was used to inoculate
eight plants dusted with carborundum (three leaves per plant).
2.3. Western blot analysis
Samples from infected plants homogenized in PBS-Tween-PVP buf-
fer (1UPBS, 0.5 g/l Tween 20 and 2% polyvinylpyrrolidone K25) [23]
or in 5 mM sodium phosphate pH 7.5 were separated by SDS-poly-
acrylamide gel electrophoresis, transferred to a nitrocellulose mem-
brane and subjected to immunoreaction as described [24]. The anti-
PPV monoclonal antibody (MAb) 5B was obtained from REALISA
kit (Durviz). The anti-CPV MAb 3C9 has been previously described
[25]. The second antibody was a peroxidase-conjugated goat anti-
mouse IgG purchased from Jackson ImmunoResearch Laboratories.
The peroxidase reaction was developed with 4-chloro-1-naphthol.
2.4. Immunocapture RT-PCR (IC-PCR)
Samples from infected plants homogenized in PBS-Tween-PVP
bu¡er were incubated for 2 h at 37‡C in tubes previously coated
with anti-PPV IgG, and then, after two washing steps with PBS-
Tween bu¡er, reverse transcription-PCR (RT-PCR) was performed
as previously described [23].
2.5. Immunization of animals
Groups of ¢ve 3-week-old BALB/c mice were immunized intraper-
itoneally on days 0 and 20. Di¡erent amounts of puri¢ed PPV-CPV,
PPV-2CPV and PPV virions in PBS were emulsi¢ed in the same vol-
ume of complete Freund’s adjuvant (Sigma) for the ¢rst inoculation
and incomplete Freund’s adjuvant (Sigma) for the subsequent booster.
Immunized mice were bled on days 0 and 35, and the sera were pooled
and tested by ELISA for titers of anti-peptide, anti-CPV and anti-
PPV antibodies, and by a monolayer protection assay for CPV-neu-
tralizing activity.
For New Zealand White rabbits (5^6 weeks old), the antigen used
for immunization varied between 5 Wg and 1 mg of chimeric PPV-
CPV or PPV-2CPV as indicated in the tables. Groups of two or three
animals received two injections with the same dose of chimeric virus
with a 21-day interval, by the intramuscular route, with complete and
incomplete Freund’s adjuvants (Sigma), respectively. Blood samples
were taken before starting experiments and 15 days after the second
immunization, and sera were tested as before.
2.6. ELISAs
For antigenicity assays, a DASI-ELISA was carried out with in-
creasing amounts of PPV, PPV-CPV and PPV-2CPV puri¢ed virions
following the protocol described in the REALISA kit (Durviz). The
anti-PPV MAb 5B (supplied in the kit) and the anti-CPV MAb 3C9
were used in the assays.
Three indirect ELISAs were carried out to detect peptide-, CPV-
and PPV-speci¢c antibodies in immunized animals. Peptide 2L21
which corresponds to the N-terminus of CPV VP2 [21] was synthe-
sized in Escherichia coli as a ubiquitin-fusion protein (kindly provided
by Igen, USA). Peptide 2L21, puri¢ed CPV and puri¢ed PPV-R3,
respectively, were used as antigen sources. Polystyrene microtiter
plates (Labsystem, Finland) were coated with the peptide, puri¢ed
CPV or PPV at 5 mg/ml diluted in 50 mM carbonate bu¡er, pH
9.6, overnight at 4‡C. Plates were incubated at 37‡C for 1 h with
the ¢rst antibody (rabbit or mouse sera) diluted in blocking bu¡er
(350 mM NaCl, 0.05% Tween 20 in PBS). Peroxidase-labeled protein
A (Sigma) or anti-mouse IgG (Pierce) were diluted 1/1000 in blocking
bu¡er and used as corresponding conjugate by incubation for 1 h at
37‡C. Washes were performed with PBS containing 0.05% Tween 20.
Horseradish peroxidase activity was detected by adding ABTS (2,2P-
azino-di(ethyl-benzothiazoline)) (Sigma) as substrate and stopped
after 15 min with 2% SDS. The optical density of samples was deter-
mined at 405 nm (Bio-Tek Instruments).
2.7. In vitro protection assays
To determine the ability of the speci¢c rabbit and mouse sera to
neutralize the virus in vitro, a CRFK cell monolayer-protection assay
was performed as previously described [25].
2.8. Immunogold labeling assay
10 Wl of a 0.1 Wg/ml dilution of PPV and PPV-CPV were adsorbed
onto formvar grids for 2 min. After an 8 min washing step with TBG
bu¡er (30 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% gelatine, 0.1%
bovine serum albumin) both samples were incubated with either a
polyclonal antibody against PPV or MAb 3C9 for 8 min. After ¢ve
washing steps with TBG bu¡er, samples were incubated for 8 min
with 5 nm gold-labeled anti-rabbit IgG or 10 nm gold-labeled anti-
mouse IgG, depending on the ¢rst antibody used. Grids were ¢nally
washed ¢ve times with TBG bu¡er and three times with milliQ water
before staining with 2% uranyl acetate for 30 s. Micrographs were
obtained in a JEOL 1200EXII electron microscope.
3. Results
3.1. Construction of an expression vector based on PPV
As a ¢rst attempt to express foreign sequences in the ami-
no-terminal part of PPV CP, we decided to replace PPV se-
quences by foreign ones. NAT mutants are natural precedents
of viable PPV CP deletion mutants. NAT-imitating mutants
were created by site-directed mutagenesis of the PPV full-
length clone pGPPV [22]. Two mutated full-length clones
were constructed. pGPPV-NAT has the 45 nt deletion found
in natural NAT mutants, but no other sequence changes com-
pared to pGPPV. pGPPV-NATMluI has the same deletion as
pGPPV-NAT but also additional nucleotide changes near the
deletion point, which create a unique MluI restriction site
(Fig. 1A). This new construct allowed us to clone foreign
sequences encoding the peptides of interest.
Capped transcripts from the mutant and wild-type clones
were inoculated onto Nicotiana clevelandii plants. Both mu-
tants were able to infect plants. The time course of infection
and symptomatology were similar to those of wild-type-in-
fected plants. Western blot analysis of infected plants showed
that PPV-NAT and PPV-NATMluI mutants accumulated to
a similar extent as wild-type PPV. As expected, the CPs of the
mutant viruses showed higher electrophoretic mobilities than
wild-type CP (Fig. 2A). IC-PCR of samples from infected
plants ampli¢ed bands of the expected sizes for each mutant
(Fig. 2B). The stability of the mutated sequence in the prog-
eny virus was corroborated by MluI digestion (Fig. 2B) and
nucleotide sequencing of the IC-PCR-ampli¢ed products (data
not shown).
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3.2. Construction and puri¢cation of PPV-CPV chimeras
The pGPPV-NATMluI clone was used to introduce foreign
sequences in the PPV genome. A 45 nt CPV sequence that
reestablished the number of amino acids of wild-type PPV-
CP was introduced at the MluI site creating pGPPV-CPV
(Fig. 1B). This sequence encodes a 15 aa peptide of CPV
VP2 protein that had previously been described to induce
complete protection when experimental animals were immu-
nized with it [20]. To test if this site could accommodate
larger sequences and if a tandem repetition of the CPV epi-
tope could improve the immunogenicity of the chimera, a
dimer of the CPV sequence was introduced, creating
pGPPV-2CPV. This clone contains a 90 nt foreign sequence
and a 45 nt increased size compared to PPV wild-type ge-
nome, which results in a CP 15 aa larger than wild-type (Fig.
1B). Transcripts from both chimeras were able to infect
N. clevelandii plants with similar characteristics to those of
wild-type.
Virions were puri¢ed from N. clevelandii plants infected
with PPV, PPV-CPV and PPV-2CPV. The yield after puri¢-
cation of both chimeric viruses was similar to that of PPV and
there seemed to be no di¡erence in virion stability either after
puri¢cation treatments or under commonly used storage con-
ditions.
3.3. Immunocharacterization of chimeric viruses
Puri¢ed virion samples were analyzed by Coomassie blue
staining and by immunoreaction against PPV- and CPV-spe-
ci¢c MAbs. Although PPV and PPV-CPV CPs have the same
number of amino acids, they have a slightly di¡erent electro-
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Fig. 1. Schematic representation of the mutant and chimeric PPV constructs. A: NIb and CP amino acid sequences of PPV, PPV-NAT and
PPV-NATMluI at the deletion site are compared, indicating their position in the genomic map of the virus. Deleted amino acids are repre-
sented by points. CP cistron nucleotide sequences of PPV-NAT and PPV-NATMluI are also compared at that site. The black box shows the
MluI restriction site. B: Amino acid sequence of PPV, PPV-CPV, PPV-2CPV and PPV-NATMluI at the NAT deletion site. Foreign and de-
leted amino acids are represented by bold letters and points, respectively.
Fig. 2. Characterization of mutant PPV accumulated in systemically infected N. clevelandii leaves. A: Western blot analysis of extracts from
plants infected with transcripts synthesized in vitro from pGPPV (lane 1), pGPPV-NAT (lane 2), and pGPPV-NATMluI (lane 3). The immuno-
reaction was carried out with the anti-PPV MAb 5B. B: IC-PCR products (nt 8390^8900 of the PPV genome [28]) ampli¢ed from a healthy
plant (lane 1) and from plants infected with wild-type PPV (lane 3), PPV-NAT (lane 4) and PPV-NATMluI (lane 5). Lanes 6 and 7 show the
result of MluI digestion of the PPV-NAT and PPV-NATMluI ampli¢cation products, respectively. HindIII restriction fragments of phage P29
DNA were used as size markers (lane 2).
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phoretic mobility, as expected from their di¡erent amino acid
composition (Fig. 3A). The DNA fragments ampli¢ed by IC-
PCR corresponding to the CP amino-terminal region of PPV
and PPV-CPV showed the same size (Fig. 3B), indicating that
no deletions were taking place in the chimeric virus inserted
sequence. The DNA fragment ampli¢ed from the PPV-2CPV
chimera showed the expected size increase compared to PPV
and PPV-CPV. These conclusions were con¢rmed by restric-
tion digestion with HincII as there is a restriction site in the
CPV sequence (Fig. 3B), and by sequencing of the ampli¢ed
products, which also veri¢ed the absence of second mutations
introduced during replication of the chimeric viruses (data not
shown). Some chimeras based on plant viruses encoding for-
eign sequences have shown a tendency to lose the foreign
insert after a number of replication rounds or plant passages
[6]. PPV-CPV and PPV-2CPV chimeric viruses were geneti-
cally stable in plants after up to 30 days and PPV-CPV mu-
tant remained stable after four subsequent passages in
N. clevelandii plants (data not shown).
As expected, all puri¢ed virions were recognized by MAb
5B raised against PPV CP in Western blot analysis. Only
PPV-CPV and PPV-2CPV virions were recognized by MAb
3C9 against the CPV epitope. There was a strong reaction of
the latter antibody with both chimeras and no background
reaction with wild-type PPV (Fig. 3A).
The antigenicity of the chimeric viruses was assayed by
DASI-ELISA (Fig. 4). All viruses were recognized at similar
levels by the anti-PPV antibody, the saturation being reached
above 100 ng. As expected, wild-type PPV was not recognized
by the 3C9 antibody. PPV-CPV and PPV-2CPV chimeras re-
acted with this anti-CPV MAb. ELISA values for PPV-2CPV
were somewhat higher, reaching saturation at lower amounts
than PPV-CPV, probably re£ecting the fact that PPV-2CPV
holds two copies of the 6L15 epitope.
Immunogold labeling experiments were performed compar-
ing PPV and PPV-CPV. The morphology of both virus par-
ticles seemed to be similar. Both PPV and PPV-CPV were
gold-labeled when incubated with a polyclonal antibody
against PPV, but only PPV-CPV was labeled when the incu-
bation was instead performed with MAb 3C9 (Fig. 5).
3.4. Immunogenicity of the PPV-CPV chimeras
To test the ability to stimulate production of CPV-speci¢c
antibodies, several amounts of PPV-CPV chimeras were used
to immunize mice. Table 1 shows ELISA titrations at day 35
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Fig. 3. Characterization of chimeric PPV. A: Coomassie blue staining (lanes 1^3), Western blot analysis with anti-PPV MAb 5B (lanes 4^6)
and anti-CPV MAb 3C9 (lanes 7^9) of wild-type PPV (lanes 1, 4 and 7), PPV-CPV (lanes 2, 5 and 8) and PPV-2CPV (lanes 3, 6 and 9) puri-
¢ed virions. B: IC-PCR products (nt 8390^8900 of the PPV genome [28]) ampli¢ed from a negative control (lane 1) and from wild-type PPV
(lane 3), PPV-CPV (lane 4) and PPV-2CPV (lane 5) puri¢ed virion samples. Lanes 6, 7 and 8 show the HincII digestion of wild-type PPV,
PPV-CPV and PPV-2CPV ampli¢cation products, respectively. HindIII restriction fragments of phage P29 DNA were used as size markers
(lane 2).
Fig. 4. DASI-ELISA of PPV, PPV-CPV and PPV-2CPV puri¢ed
virions using anti-PPV MAb 5B (left) and anti-CPV MAb 3C9
(right).
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of the various sera expressed as log reciprocal antibody dilu-
tion. All mice developed antibodies to PPV showing a good
correlation between the amount of antigen used and anti-PPV
titer. Doses as low as 0.05 Wg of PPV-2CPV were able to
induce anti-peptide and anti-CPV antibodies, albeit at low
titers, 1.7 and 1.0, respectively. The strongest response against
peptide and CPV was developed in mice immunized with 5 Wg
of PPV-2CPV (group 6), reaching ELISA titers of 4.4 and 3.7
for anti-peptide and anti-CPV antibodies, respectively. These
titers were slightly higher than those obtained in mice immu-
nized with the same amount of chimeric particles containing
the monomer (group 2). Group 3, immunized with the highest
dose (50 Wg), responded to CPV peptide to a signi¢cantly
lower extent.
To study the immunogenicity of the chimeric particles in
rabbits, a second immunization experiment was carried out.
Seven groups of two or three rabbits were immunized with
di¡erent doses of PPV-CPV or PPV-2CPV with a 21-day in-
terval (Table 2). In general, anti-PPV antibody levels in-
creased with the antigen dose. All rabbits immunized with
chimeric particles elicited detectable anti-peptide and anti-
CPV responses. The highest antibody titers were obtained
when rabbits were immunized with 100 Wg/dose of PPV-
CPV, reaching titers of 4.1 for the peptide and 3.7 for CPV.
The second highest antibody titers were observed in rabbits
immunized with 500 Wg/dose of PPV-CPV or PPV-2CPV, sug-
gesting that the most e¡ective amount of chimeric particles to
stimulate production of CPV-speci¢c antibodies in rabbits was
between 100 and 500 Wg, administered in two doses. The use
of higher doses like 1 mg did not increase proportionally the
CPV-speci¢c response as observed in mice, probably due to
antigenic saturation. The insertion of dimers instead of mono-
mers of the epitope sequence seems not to increase signi¢-
cantly the rabbit CPV-speci¢c response in contrast to that
observed in mice.
3.5. CPV-neutralizing antibody response elicited by the
PPV-CPV chimeras
To assess the ability of the chimeric PPV-CPV particles to
induce CPV-neutralizing antibodies, a monolayer-protection
assay was carried out with immunized mouse and rabbit
sera in the absence of complement. Tables 1 and 2 show the
neutralization titers of mouse and rabbit sera, respectively. All
mice elicited detectable levels of CPV-neutralizing antibodies,
except group 4, immunized with 0.05 Wg of PPV-2CPV, which
showed almost no response to CPV or PPV. The highest neu-
tralizing response was achieved by group 6 mice immunized
with 5 Wg of PPV-2CPV, with a titer of 3.2, which is slightly
higher than the 2.6 titer obtained with the same dose of
monomer chimeric particles.
In the rabbit immunization experiment, 12 out of 16 ani-
mals showed detectable CPV-neutralizing antibodies, ranging
between titers of 1.0 for rabbits immunized with 5 Wg of PPV-
CPV and 2.9 for rabbits immunized with 100 Wg of PPV-CPV
or 500 Wg of PPV-2CPV, con¢rming that the most adequate
amount of chimeric particles for rabbits was between 100 and
500 Wg. Sera from rabbits immunized with chimeric particles
containing the dimer were not especially e¡ective in inducing
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Fig. 5. Immunogold labeling of PPV (A and C) and PPV-CPV (B
and D) incubated with an anti-PPV polyclonal antibody (A and B)
and anti-CPV MAb 3C9 (C and D).
Table 1
Antibody response to chimeric PPV-CPV and PPV-2CPV particles in mice
Mouse group Dose ELISA NTa
Peptideb CPVc PPVd
1 0.5 Wg PPV-CPV 3.8e 2.8 4.4 2.3f
2 5 Wg PPV-CPV 4.1 3.4 5.0 2.6
3 50 Wg PPV-CPV 2.6 1.9 5.3 1.9
4 0.05 Wg PPV-2CPV 1.7 1.0 2.3 ^
5 0.5 Wg PPV-2CPV 3.8 2.5 4.4 1.9
6 5 Wg PPV-2CPV 4.4 3.7 5.3 3.2
7 5 Wg PPV ^ ^ 5.0 ^
8 50 Wg PPV ^ ^ 5.0 ^
aCPV neutralization assay as described in Section 2.
bELISA for anti-peptide antibodies. Peptide 2L21 was used as antigen.
cELISA for anti-CPV antibodies. Puri¢ed CPV was used as antigen.
dELISA for anti-PPV antibodies. Puri¢ed PPV was used as antigen.
eELISA titers were determined 2 weeks after the second immunization and are expressed as 3log of serum dilution which yielded absorption values
three times the blank (preimmunization serum). Average values for all group mice are shown. ^: no detectable immunoreaction (3log of lowest
serum dilution tested: 1.0).
fNeutralization titers were determined 2 weeks after the second immunization and are expressed as 3log of highest serum dilution able to protect
cell monolayer from CPV infection. ^: no detectable neutralizing activity (3log of lowest serum dilution tested: 1.0). Average values for all group
mice are shown.
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neutralizing activity, which is in agreement with the ELISA
results. As expected, rabbit sera with a very low response
against VP2 peptide were not capable of neutralizing CPV.
4. Discussion
Viruses have been demonstrated to be useful expression
vectors in plants [26,27]. In particular, di¡erent plant viruses
have been developed as presentation systems for the expres-
sion of foreign peptide sequences [2^8]. The PPV-based vector
reported in this paper is, to our knowledge, the ¢rst descrip-
tion of a potyvirus being used for this purpose.
The amino-terminal part of the virus CP was chosen as
cloning site for two reasons. First, it is encoded by the most
variable region, in length and sequence, of the potyvirus ge-
nome. This fact, suggesting a potential capability of the po-
tyvirus genome to hold di¡erent sequences in length in this
region, is especially remarkable taking into account that some
viral systems only tolerate short genome insertions. Second,
the amino-terminal part of the PPV CP is exposed on the
virion surface and is highly immunogenic [17].
NAT mutants are natural examples of modi¢cations in the
amino-terminal part of PPV CP. A PPV-based expression
vector (PPV-NATMluI) was constructed by removing from
a full-length cDNA clone the dispensable region deleted in
these natural mutants, and introducing a restriction site to
facilitate the cloning of foreign sequences. This vector should
be restricted to inoculated plants since part of the CP region
required for aphid transmission is included in the deleted se-
quence. This safety point is very relevant with reference to
large-scale production in the ¢eld.
A CPV antigenic peptide sequence, in both single and tan-
dem form, was cloned in the PPV-NATMluI vector. The two
chimeras (PPV-CPV and PPV-2CPV) were viable and genet-
ically stable, showing that the insertion site is somehow per-
missible to modi¢cation and that inserts as long as 30 amino
acids can be tolerated without any deleterious e¡ect on virus
growth. The amino-terminal part of potyviruses has been im-
plicated in systemic movement [13,14], the mutants described
here seem to have no reduced long distance movement, so
sequences required for such function have to be restricted to
other parts of the CP amino-terminal region. The yield of the
chimeric virus particles is similar to that of wild-type PPV,
besides chimeric virions are stable after puri¢cation treat-
ments and storage.
The particulate and repetitive structure of potyvirus virions
(about 2000 copies of a single protein), together with the sur-
face exposure of the potyvirus CP amino-terminal part, pre-
sumes that chimeras based on PPV-NATMluI might behave
as competent antigen delivery systems for evoking strong anti-
body responses. Indeed, PPV-CPV and PPV-2CPV showed a
high antigenicity and were e⁄ciently recognized by anti-CPV
antibodies in ELISA (Fig. 4), Western blot (Fig. 3) and im-
munomicroscopy (Fig. 5) analysis, emphasizing the utility of
the PPV vector for diagnosis purposes. On the other hand,
both chimeric viruses were immunogenic and able to induce
high levels of antibodies in both mice and rabbits, but there
seems not to be a substantial di¡erence in the quality of im-
mune response induced by PPV-CPV and PPV-2CPV. The
elicited antibodies were able to neutralize CPV, although the
neutralization titers were not very high. It is foreseen that
further improvements of the system (modi¢cations in the virus
constructions and in the inoculation manner) may facilitate its
use as a source of alternative vaccines.
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